Admilparant Trial Met Primary Endpoint
The ALOFT-IPF Phase 3 study showed that the 60mg dose of admilparant successfully slowed lung-function decline.
Updated on Oct. 12, 2026 in Asthma
Live Poll
Do you trust pharmaceutical companies to deliver consistent long-term growth based on their latest trial news?
Bristol Myers Squibb announced that its ALOFT-IPF clinical trial met its primary endpoint for the drug admilparant. The 60mg dose reached statistical significance in slowing the progression of idiopathic pulmonary fibrosis over 52 weeks.
Why it matters
The study's success provides a potential new therapeutic option for patients living with idiopathic pulmonary fibrosis. This trial outcome marks a significant milestone for the drug development program as the company moves toward regulatory review.
The ALOFT-IPF trial enrolled 1,255 adults who were monitored over 52 weeks to measure changes in forced vital capacity. While the 60mg dose achieved significance, the 120mg dose failed to do so independently.
The players
Bristol Myers Squibb
This global biopharmaceutical company focuses on the discovery and development of innovative medicines for serious diseases.
The details
Participants in the trial were randomized to receive 60mg or 120mg doses twice daily, or a placebo, to evaluate drug efficacy. Safety data indicated that discontinuation rates due to side effects remained similar between the active treatment arms and the placebo group.
Timeline
Bristol Myers Squibb reported a net loss of $11.911bn in 2024 Q1.
The company reported a net income of $3.317bn in 2026 Q2.
The short-sale ratio was measured at 0.669 on September 30, 2026.
The short-sale ratio decreased to 0.294 on October 9, 2026.
Topline results for the ALOFT-PPF trial are expected in early 2027.
The Big Picture
The success of the ALOFT-IPF Phase 3 clinical trial follows the standard regulatory path for testing new respiratory therapies against established clinical baselines. This story updates the progress of the ALOFT-IPF program following its successful achievement of the primary endpoint.
The clinical success of the 60mg dose offers hope for new treatment options for patients managing the decline associated with idiopathic pulmonary fibrosis. Future regulatory engagement may eventually lead to greater availability of this therapy for those who meet specific clinical criteria.
The takeaway
Patients should monitor medical literature updates regarding the forthcoming presentation of detailed trial data. These results mark a promising shift toward potential new treatment protocols for those suffering from chronic lung-function decline.
What happens next
Detailed results from the ALOFT-IPF trial are expected to be presented at a future medical meeting. Additionally, topline results for the related ALOFT-PPF trial are expected to be released in early 2027.
Further reading
For additional context on the treatment of respiratory conditions, visit the Asthma section.
Live Poll
Do you trust pharmaceutical companies to deliver consistent long-term growth based on their latest trial news?
